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LPIN1 encodes lipin-1, a phosphatidic acid phospha-
tase (PAP) enzyme that catalyzes the dephosphory-
lation of phosphatidic acid to form diacylglycerol.
Homozygous LPIN1 gene mutations cause severe
rhabdomyolysis, and heterozygous LPIN1 missense
mutations may promote statin-induced myopathy.
We demonstrate that lipin-1–related myopathy in
the mouse is associated with a blockade in autopha-
gic flux and accumulation of aberrant mitochondria.
Lipin-1 PAP activity is required for maturation of
autolysosomes, through its activation of the protein
kinase D (PKD)-Vps34 phosphatidylinositol 3-kinase
signaling cascade. Statin treatment also reduces
PKD activation and autophagic flux, which are com-
pounded by diminished mammalian target of rapa-
mycin (mTOR) abundance in lipin-1-haploinsufficent
and -deficient muscle. Lipin-1 restoration in skeletal
muscle prevents myonecrosis and statin toxicity
in vivo, and activated PKD rescues autophagic flux
in lipin-1-deficient cells. Our findings identify lipin-1
PAP activity as a component of the macroautophagy
pathway and define the basis for lipin-1-related
myopathies.
INTRODUCTION
Lipin-1 is a phosphatidic acid phosphatase (PAP) enzyme,
which converts phosphatidic acid (PA) to diacylglycerol (DAG),
a precursor of triacylglycerol and phospholipids (Donkor et al.,
2007; Han et al., 2006). Lipin-1 is also a coregulator of DNA-
bound transcription factors (Finck et al., 2006; Kim et al., 2010;
Peterson et al., 2011; Sugden et al., 2010), which in some cases
requires its PAP activity (Peterson et al., 2011). Lipin-1 is a target
of the mechanistic target of rapamycin complex 1 (mTORC1),
and lipin-1 subcellular localization and function are regulated
by mTORC1-dependent phosphorylation at multiple sites (Eaton
et al., 2013; Harris et al., 2007; Huffman et al., 2002; PetersonCelet al., 2011). Through these activities, lipin-1 and its orthologs
in diverse species regulate adipogenesis, lipid metabolism, nu-
clear envelope and mitochondrial morphology, and vacuole
fusion (Csaki et al., 2013; Pascual and Carman, 2013).
Recently, recessive LPIN1 gene mutations have been identi-
fied as a cause of childhood rhabdomyolysis (Bergounioux
et al., 2012; Michot et al., 2010, 2012; Zeharia et al., 2008).
Rhabdomyolysis, a severe form of myopathy, is characterized
by breakdown of skeletal muscle resulting in leakage of mus-
cle-cell contents, such as electrolytes, creatine kinase, and
myoglobin, into the circulation. Episodes of LPIN1-related rhab-
domyolysis appear to be precipitated by febrile illness, exercise,
fasting, or anesthesia (Bergounioux et al., 2012; Zeharia et al.,
2008). Nearly all LPIN1 mutations that cause childhood rhabdo-
myolysis are nonsense or deletion mutations, which are pre-
dicted to result in inactive protein (Michot et al., 2010, 2012;
Zeharia et al., 2008). Myopathy has also been reported in individ-
uals that are heterozygous for LPIN1 missense mutations in
response to statin drug treatment (Michot et al., 2012; Zeharia
et al., 2008). Statins are widely prescribed cholesterol-lowering
drugs that reduce the incidence of cardiovascular diseases.
An estimated 1%–5% of statin drug users complain of muscle
symptoms, and a small proportion develop rhabdomyolysis
(Mohassel and Mammen, 2013; Thompson et al., 2003). The un-
derlying mechanisms for statin myotoxicity are not understood,
but there is evidence that underlying genetic variations may pre-
dispose some individuals (Link et al., 2008; Mangravite et al.,
2013; Needham andMastaglia, 2014). Relevant to the pathology
of LPIN1-related myopathies, lipin-1 accounts for the majority of
PAP activity in human and mouse skeletal muscle (Donkor et al.,
2007; Harris et al., 2007; Michot et al., 2013), and the transgenic
modulation of muscle lipin-1 levels alters energy balance (Phan
and Reue, 2005). Human lipin-1-deficient muscle and myoblasts
accumulate neutral lipid droplets (Michot et al., 2012, 2013), but
it is unclear how this relates to the massive muscle breakdown in
affected patients.
We sought to elucidate the mechanism underlying myopathy
both in lipin-1 deficiency and in response to statin treatment in
the presence of reduced lipin-1 activity. We identified a role for
lipin-1 in autophagy and determined that lipin-1 deficiency and
statin drug effects converge at specific points of lipid meta-
bolism that influence autophagic flux.l Metabolism 20, 267–279, August 5, 2014 ª2014 Elsevier Inc. 267
Figure 1. Myopathy in Lipin-1-Deficient and Statin-Treated Lipin-1-Haploinsufficient Mice
(A) Lpin1 mRNA levels in muscle of lipin-1-deficient (fld/fld), heterozygous (wt/fld), and wild-type (wt/wt) mice (n = 6 mice/genotype).
(B) Plasma creatine kinase (CK) activity in mice fasted 16 hr and refed for 5 hr (n = 5–12 mice per group).
(C) Left: representative image of necrotic myofibers (enclosed in dashed line circles) in transverse section of lower hindlimb muscle (H&E stain). Right: necrotic
myofiber frequency as a percentage of total fiber number (n = 5 mice per group). Scale bars, 50 mm.
(D) Left: representative image of centrally nucleated myofibers (arrowheads) in transverse section of lower hindlimb muscle (methyl green stain). Right: centrally
nucleated myofiber frequency as a percentage of total fiber number (n = 5). Scale bars, 50 mm.
(E) Top: oil red O (ORO)-stained sections from tibialis anterior muscle. Bottom: NADH-tetrazolium reductase (NADH-TR) staining of sections adjacent to those
stained with ORO. Lipid accumulation was present in type I fibers (dark blue), but not type II fibers (light blue). Scale bars, 50 mm.
(legend continued on next page)
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Myonecrosis in Lipin-1-Deficient and Statin-Treated
Lipin-1-Haploinsufficient Mice
To investigate the pathoetiology of inherited and statin-induced
lipin-1-related myopathies, we utilized mouse models with
lipin-1 deficiency (Lpin1fld/fld mice, denoted ‘‘fld/fld’’; Pe´terfy
et al., 2001) or with half the normal lipin-1 levels (Lpin1wt/fld
mice, denoted ‘‘wt/fld’’) (Figure 1A). LPIN1-related rhabdomyo-
lytic episodes are associated with metabolic stress, including
fasting. We found that muscle damage is triggered in fld/fld
mice by fasting for 16 hr followed by 5 hr refeeding. These con-
ditions elevated creatine kinase (CK) levels and were employed
throughout our studies. The CK levels in fld/fld mice were exac-
erbated by treatment with Pravastatin (375 mg/day/mouse in the
drinking water for 11 weeks) (Figure 1B). Heterozygous (wt/fld)
mice had normal CK levels under basal conditions, but increased
above wild-type levels following statin treatment (Figure 1B).
Myofibrillar necrosis was evident in fld/fldmice and enhanced
by statin treatment (Figure 1C). Muscle from fld/fld mice also
exhibited centrally located myonuclei, indicative of regenerating
fibers (Charge´ and Rudnicki, 2004), which became more preva-
lent upon statin treatment (Figure 1D). Centrally nucleated fibers
were not observed in wt/fld muscle under the basal conditions
but became apparent after statin treatment (Figure 1D). Thus,
lipin-1-deficient muscle exhibits necrosis and regeneration,
and statin treatment promotes muscle damage in lipin-1-hap-
loinsufficient mice and lipin-1-deficient mice.
Since lipin-1 catalyzes a step in triacylglycerol (TAG) biosyn-
thesis, we expected that fld/fld muscle would have reduced
neutral lipid storage. Staining of muscle with oil red O revealed
an unexpected accumulation of neutral lipid droplets in lipin-1-
deficient muscle, primarily in type I fibers (Figures 1E and S1A,
available online). This pattern of lipid accumulation is similar to
that reported in a LPIN1-deficient patient (Michot et al., 2012)
and in a subset of human statin-intolerant myopathy patients
(Phillips et al., 2002); the identity of neutral lipid accumulating
in these patients has not been determined. Biochemical ana-
lyses revealed that fld/fld muscle contained very little TAG and
that wt/fld muscle contained approximately 50% of that of
wild-type levels (Figure 1F). By contrast, cholesteryl ester levels
were elevated by 2-fold in fld/fld muscle under the basal condi-
tion and were elevated further after statin treatment (Figure 1F).
Cholesteryl ester accumulation likely accounts for the neutral
lipid droplets observed in lipin-1-deficient muscle. Free fatty
acid levels were also elevated in fld/fld muscle in basal and
statin-treated conditions and in wt/fld muscle after statin treat-
ment (Figure 1F). We did not detect increased expression of fatty
acid synthetic genes in fld/fld muscle (Figure S1B), and it is
possible that fatty acids accumulating in muscle are derived
from other tissues. Given the role of lipin-1 in coactivation of he-
patic fatty acid oxidation genes (Finck et al., 2006), we examined
expression of known target genes (Cpt1b,Acadm,Acadl,Acox1)
inmuscle. Gene expression levels were similar in fld/fld andwild-(F) Lipid quantification in lower hindlimb muscle from mice under basal and statin
with electrospray ionization mass spectrometry (PA) (n = 3–6). TG, triacylglycerol
*p < 0.05; **p < 0.01 versus indicated group; xp < 0.05 versus all other groups.
All bar graphs show the mean ± SD.
Celtype muscle (Figure S1C), suggesting that fatty acid accumula-
tion is not a result of impaired lipin-1 coactivator function.
Analysis of phospholipid and sphingolipid content by electro-
spray ionization mass spectrometry revealed substantial alter-
ations in lipin-1-deficient muscle. PA, the substrate for lipin-1
enzymatic activity, was elevated 3-fold in fld/fldmuscle (Figures
1F and S1D). In addition, fld/fld muscle had elevated levels of
ether phosphatidylcholine (ePC) and ceramides (Figure S1D).
Thus, the accumulation of several aberrant lipid species (choles-
teryl ester, fatty acids, various phospholipids, and ceramides)
may contribute to altered metabolism in lipin-1-deficient muscle.
Muscle Lipin-1 Rescues Basal and Statin-Induced
Myonecrosis in Lipin-1-Deficient Mice
To determine whether the loss of lipin-1 locally in skeletal muscle
is responsible for myonecrosis observed in fld/fld mice, we
rescued lipin-1 expression with a muscle-specific lipin-1 trans-
gene (Phan and Reue, 2005). By crossing the Mck-lipin-1 trans-
gene into fld/fld mice, we generated animals with lipin-1
exclusively in skeletal muscle (referred to as fld/fld-MCK Tg;
Figure 2A). Transgenic restoration of lipin-1 in muscle of fld/fld
mice prevented muscle damage, as indicated by normalized
CK levels and reduced myocyte turnover (Figures 2B and 2C),
and largely normalized the reduced myofiber size that occurs in
fld/fld soleus and tibialis anterior muscle (Figure S2A). The resto-
ration of lipin-1 fld/fld muscle prevented the accumulation of
neutral lipids in type 1 fibers (Figures 2D and S2B), increased
TAG levels, and normalized cholesteryl ester, fatty acids, PA,
ePC, andceramide levels (Figures 2E–2HandS2C). Furthermore,
lipin-1 expression in muscle protected against the statin-associ-
ated muscle damage in both wt/fld and fld/fld mice (Figures 2B,
2C, and S2D).
Lipin-1 Deficiency Impairs Mitochondrial Function and
Autophagy in Muscle
The aberrant lipid profile in type I muscle fibers of lipin-1-defi-
cient muscle led us to investigate mitochondrial activity. We
examined mitochondrial ultrastructure in fld/fldmuscle by trans-
mission electron microscopy (TEM). The fld/fld soleus muscle
exhibited large, misshapen mitochondria. After statin treatment,
disorganized cristae were also evident (Figures 3A and S3A).
By contrast, mitochondria of wild-type muscle had normal
morphology, even after statin treatment. Increased mitochon-
drial number was also evident in fld/fld muscle, as judged
by the increased levels of mitochondrial DNA relative to
genomic DNA (Figure 3B). To assess mitochondrial function,
we measured oxygen consumption in soleus muscle from wild-
type and fld/fld mice. Basal oxygen consumption rates did not
differ, but when challenged with a mitochondrial uncoupler,
wild-type muscle responded with the expected increase in oxy-
gen consumption, whereas the response in fld/fld muscle was
severely blunted (Figure 3C).
Mitochondrial quality is tightly controlled by autophagy, a pro-
cess by which damaged mitochondria are degraded (Wang and-treated conditions. Measurements were made biochemically (TG, CE, FFA) or
; CE, cholesteryl esters; FFA, unesterified fatty acids; PA, phosphatidatic acid.
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Figure 2. Muscle Lipin-1 Transgene Ameliorates Muscle Breakdown and Statin-Induced Myopathy
(A) RT-PCR analysis of Lpin1 mRNA in tissues of wild-type (wt/wt), fld/fld, or fld/fld mice with MCK-lipin-1 transgene (fld/fld-MCK Tg).
(B) Muscle lipin-1 transgene normalizes plasma CK to wild-type levels in fld/fld mice and in wt/fld mice treated with statin (n = 3–6 mice per group).
(C) Muscle lipin-1 transgene reduces the frequency of centrally nucleatedmyofibers in fld/fldmice under basal conditions. Left: representative centrally nucleated
myofibers (arrowheads) in transverse section of hindlimb muscle (methyl green stain). Right: frequency of centrally nucleated fibers as percentage of total fiber
number (n = 3–6). Scale bars, 50 mm.
(D)Muscle lipin-1 transgeneprevents theaccumulationof neutral lipiddroplets inskeletalmuscleoffld/fldmice.Staining isasdescribed inFigure1E.Scalebars, 50mm.
(E–H) Lipid levels in lower hindlimb muscle of fld/fld-MCK Tg and littermates of all genotypes, as indicated (n = 3–6). Lipid abbreviations are as in Figure 1F.
*p < 0.05; **p < 0.01 versus indicated groups; xp < 0.05 versus all other groups.
All bar graphs show the mean ± SD.
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Lipin-1 Regulates Autophagy ClearanceKlionsky, 2011). A knockdown in the expression of the lipin
ortholog in Drosophila (Dlipin) leads to an accumulation of
abnormal mitochondria and autophagosomes in the fat body
(Ugrankar et al., 2011). We hypothesized that damaged mito-
chondria might accumulate in lipin-1-deficient muscle because
of impaired autophagy. Autophagy is induced under starvation
and other conditions and begins with the formation of a limiting
membrane that encompasses cytosolic proteins and organelles
by forming a vesicular autophagosome; the autophagosome
then fuses with a lysosome to produce an autolysosome and de-
grades its contents (Wang and Klionsky, 2011). We assessed the
induction of autophagy by examining the levels of the autopha-
gosome marker, microtubule-associated protein-1 light chain 3
(LC3)-II (Kabeya et al., 2000).
In wild-type muscle, fasting led to the expected induction of
LC3-II, which was not apparent after feeding (Figure 3D, upper
panel). Muscle from fld/fldmice induced autophagosome forma-
tion in response to fasting but maintained high levels of LC3-II
even after refeeding; statin treatment further elevated the levels
of LC3-II in fld/fld mice (Figure 3D, lower panel). We also esti-
mated autophagic flux by quantitating the levels of p62, an auto-
phagy-selective substrate (Mizushima et al., 2010). Compared to
wild-type muscle, fld/fld muscle accumulated twice as much
p62 (Figures 3D and S3B). Interestingly, statin treatment caused
a modest increase in p62 protein levels in wild-type muscle,
albeit less than that observed in lipin-1-deficient muscle (Fig-
ure S3B). Neither lipin-1 deficiency nor statin treatment influ-
enced p62 mRNA expression levels, consistent with effects on
p62 clearance rather than synthesis (Figure S3B). The LC3-II
and p62 levels in fld/fld muscle were restored to wild-type
levels by expression of the muscle-specific lipin-1 transgene
(Figure 3E). These studies demonstrate that lipin-1 is dispens-
able for the formation of autophagosomes but is required for
clearance of autolysosome cargo (e.g., LC3-II and p62).
To learn more about the role of lipin-1 in autophagy, we
assessed the localization of lipin-1 by costaining C2C12 myo-
tubes with antibodies against endogenous lipin-1 and LAMP-1,
a lysosomal protein that has a role in the fusion of lysosomes
with phagosomes (Huynh et al., 2007). Under basal conditions,
lipin-1 protein had a diffuse cytoplasmic distribution (Figure 3F,
left panels). Treatment with rapamycin, which inhibits mTOR
and induces autophagy, promoted migration of lipin-1 to the
perinuclear region and partial colocalization with Lamp1 (Fig-
ure 3F, middle panels). Statin treatment promoted a reorganiza-
tion of lipin-1 similar to that observed with rapamycin treatment
(Figure 3F, right panels). Thus, both the induction of autophagy
and statin treatment promote lipin-1 colocalization with lyso-
somes. To exclude the possibility that lipin-1 colocalizing with
lysosomes affects lipin-1 protein stability, we treated cells
expressing lipin-1 with inhibitors of lysosomal (chloroquine) or
proteasomal (MG-132) degradation. We found that only MG-
132 inhibited lipin-1 protein degradation (Figure 3G). This is
consistent with findings for the lipin ortholog in yeast (Pascual
et al., 2014).
Lipin-1 PAP Activity Is Required for Autophagy
Clearance
We next examined whether the PAP activity of lipin-1 was
required for autophagy using a reporter consisting of LC3 conju-Celgated to a red fluorescent protein (RFP) and a green fluorescent
protein (GFP) (RFP-GFP-LC3) (Kimura et al., 2007). This reporter
distinguishes autophagosomes (yellow signal; due to fluores-
cence from both RFP and GFP) from autolysosomes (red signal;
due to RFP alone, as GFP fluorescence is impaired in the acidic
lysosomal environment). In wild-type mouse embryonic fibro-
blasts (WT MEFs), the induction of autophagy by serum and
amino acid starvation induced the formation of autolysosomes
(red puncta), indicating progression through the autophagy
pathway (Figure 4A). Starvation-induced autolysosome forma-
tion was reduced by 50% in lipin-1-deficient MEFs (fld MEFs)
(Figures 4A and 4B). The blockade in autolysosome formation
in fld MEFs was rescued by overexpression of wild-type, but
not catalytically inactive, lipin-1 (Figure 4A, left and top right
panel). These results were confirmed by analysis of LC3-II
protein levels (Figure S4A). Rapamycin induced similar levels
of LC3-II in WT MEFs and fld MEFs, demonstrating that forma-
tion of autophagosomes is not impaired by lipin-1 deficiency.
However, fld MEFs exhibited impaired clearance of LC3-II
in response to serum starvation, which could be rescued by
wild-type, but not mutant lipin-1, expression (Figure S4A). The
requirement of lipin-1 PAP activity in autophagy was further
confirmed by the analysis of PA and DAG levels in these primary
MEFs. Compared to wild-type cells, lipin-1-deficient MEFs
contained higher PA and lower DAG levels after 6 hr starvation;
overexpression of wild-type, but not PAP-deficient lipin-1 pro-
tein, restored these lipid levels (Figure 4A, right panel).
To further explore the role of lipin-1 in autophagy clearance,
the fusion of autophagosomes with lysosomes was examined
in primary WTMEFs and fldMEFs. Starvation induced the fusion
of autophagosomes with lysosomes or late endosomes in
wild-type cells, as indicated by the perinuclear colocalization
of LC3 and LAMP-1 (Figure 4B). By contrast, lipin-1 deficiency
prevented perinuclear clustering of lysosomes upon starvation
and reduced fusion between autophagosomes and lysosomes
or late endosomes (Figures 4B and S4B). The degree of LC3-
LAMP-1 colocalization observed in wild-type MEFs is similar to
that shown in previous studies that visualize autophagosome-
lysosome fusion by this method (Germain et al., 2011; Liang
et al., 2008).
Lipin-1 Deficiency Diminishes DAG-PKD-Vps34
Activation in Muscle
The requirement for lipin-1 PAP activity in autophagy clearance
raised the possibility that lipin-1 conversion of PA to DAG is
important in this process. Indeed, it has been shown that DAG
is required for clearance of bacteria by autophagy in mammalian
cells (Shahnazari et al., 2010). The role of DAG in this process is
likely linked to its function as a lipid secondmessenger. DAG ac-
tivates a signaling cascade involving protein kinase C (PKC), with
subsequent activation of the class III phosphatidylinositol 3-ki-
nase Vps34, which is involved in autophagosome formation
and maturation (Eisenberg-Lerner and Kimchi, 2012; Shibasaki
et al., 2009; Tan et al., 2012). We hypothesized that lipin-1-
generated DAG is important in autolysosome formation and
that lack of lipin-1 impairs PKC and Vps34 activation. Below,
we describe studies to test each component of this hypothesis.
Using electrospray ionizationmass spectrometry, we identified
several DAG species with reduced levels in fld/fld musclel Metabolism 20, 267–279, August 5, 2014 ª2014 Elsevier Inc. 271
Figure 3. Lipin-1 Deficiency Impairs Mitochondrial Function and Autophagy Clearance in Muscle
(A) Representative electron micrographs showing accumulation of swollen, abnormally shaped mitochondria in fld/fld soleus muscle under the basal condition
(top) and the presence of disorganized cristae after statin treatment (bottom). Scale bar, 0.5mm.
(B) Relative mitochondrial DNA content in hindlimb muscle of mice normalized to genomic DNA (n = 5–6).
(C) Real-time analysis of oxygen consumption rate in soleus muscle under the basal condition and after addition of respiration uncoupler FCCP (mesoxalonitrile
4-trifluoromethoxyphenylhydrazone) (n = 5 mice per group). wt/wt versus fld/fld, *p < 0.05; **p < 0.01.
(D) Immunoblot analysis of LC3-I, LC3-II, and p62 proteins in the lower hindlimbmuscle. Top:mice on a chow diet were fasted for 16 hr (Fasted) or fasted 16 hr and
refed for 5 hr (Refed), as indicated. Bottom: analysis of mice maintained under basal conditions (Chow) or statin treatment (analyzed after fasting 16 hr and
feeding 5 hr).
(legend continued on next page)
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Figure 4. Lipin-1 PAP Activity Is Required
for Optimal Autolysosome Formation
(A) Left: autophagosome (yellow puncta) or auto-
lysosome (red puncta) formation in MEFs from
wild-type (WT) and fld/fld mice infected with
adenovirus expressing a control gene (LacZ), wild-
type lipin-1 (WT-lipin-1), or PAP-deficient lipin-1
(PAPdef-lipin-1). Cells were depleted of glucose
and amino acids for 6 hr. Right: quantification from
experiments shown at left. Shown at the top is the
percentage of LC3 reporter present in autolyso-
somes (80 cells per group); below that are the
cellular PA and DAG levels (n = 3). *p < 0.05; **p <
0.01. Scale bars, 10 mm.
(B) Colocalization by confocal microscopy of
endogenous LC3 (green) and LAMP-1 (red) in pri-
mary MEFs infected with adenoviruses are indi-
cated on the left. Enlargements from each of the
panels are shown on the right. Scale bars, 10 mm.
All bar graphs show the mean ± SD.
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autophagyclearance,we reconstituted fldMEFswithdipalmitoyl-
glycerol (C32:0), the most abundant of the DAG species that(E) The muscle lipin-1 transgene prevents the accumulation of LC3-I, LC3-II, and p62 proteins in lower hindlim
feeding 5 hr).
(F) Colocalization of endogenous lipin-1 (green) and LAMP-1 (red) in C2C12 myotubes visualized by confo
under control conditions (DMSO), after induction of autophagy (2 mM rapamycin) or statin treatment (10 mM
(G) Lipin-1 is degraded through the proteasome pathway. Human embryonic kidney 293 (HEK293) cells were
and treated with vehicle control, MG132, or chloroquine for an additional 20 hr at the concentrations indicated
by western blot.
All bar graphs show the mean ± SD.
Cell Metabolism 20, 267–27showed reduced levels in fld/fld muscle.
The addition of dipalmitoylglycerol to fld
MEFs did not affect autophagosome
formation in the early phase of starva-
tion-induced autophagy (Figure S5A), but
it restored autophagy clearance by reduc-
tion of the levels of LC3-II (Figure 5B).
We next assessed whether the altered
DAG profile of fld/fld muscle led to
impaired PKC activation. Themammalian
PKC family consists of approximately a
dozen isoforms, several of which are
expressed in skeletal muscle (Ellwanger
et al., 2011; Jensen et al., 2009). We
analyzed the activation of relevant PKC
isoforms bywestern blot using antibodies
directed against the phosphorylated
proteins. Most PKC isoforms in muscle
showed similar levels of phosphorylation
(activation) in wild-type and fld/fldmuscle
(Figure 5C). The exception was phos-
phorylated PKD, which was substantially
reduced in fld/fld muscle, despite normal
levels of total PKD (Figure 5C). The
muscle lipin-1 transgene largely restored
PKD activation in the muscle of fld/fldmice (Figure 5D). Statin treatment also markedly diminished
PKD activation in wild-type muscle (Figure 5E), revealing a com-
mon effect of lipin-1 deficiency and statin drug response.b muscle of fld/fld (analyzed after fasting 16 hr and
cal fluorescence microscopy. Cells were analyzed
lovastatin). Scale bar, 10 mm.
transfected with plasmids encoding lipin-1 for 16 hr
, and the indicated protein levels were determined
9, August 5, 2014 ª2014 Elsevier Inc. 273
Figure 5. Lipin-1 Deficiency Inhibits the
PKD-Vps34 Pathway in Autophagy Clear-
ance
(A) Diacylglycerol quantification by electrospray
ionization mass spectrometry in hindlimb muscle
of wild-type (wt/wt) and fld/fld mice (n = 3). The
molecular species of diacylglycerol in muscle are
represented as the number of carbons:double
bonds. *p < 0.05.
(B) Immunoblot showing addition of 1,2-dipalmi-
toyl-sn-glycerol (DPG, 100 mM) increases LC3-II
degradation in starved fld MEFs.
(C) Immunoblot assessment of the activity of
muscle protein kinase C (PKC) isoforms and pro-
tein kinase D (PKD) with the indicated antibodies.
(D) Muscle lipin-1 transgene rescues PKD activity
in fld/fld muscle in mice under basal conditions.
(E) Immunoblot analysis of PKD activity in muscle
of mice under basal (Chow) and statin-treated
conditions.
(F) Analysis of Vps34 activity in autophagy by
colocalization of PtdIns3P binding probe GFP-
p40phox and RFP-LC3 in primary MEFs after star-
vation. Left: representative confocal microscopy
images, with the presence of PtdIns3P in auto-
phagosomes indicated by yellow puncta. Right:
percentage of autophagosomes with visible yel-
low puncta, indicating the presence of PtdIns3P.
n = 80 cells per group. Scale bars, 10 mm.
All bar graphs show the mean ± SD.
(G) Expression of active PKD restores autophagy
flux in fld MEFs. Constitutively active PKD
(S738E/742E) and RFP-GFP-LC3 reporter were
cotransfected into primary MEFs. Left: represen-
tative confocal microscopy images. Red puncta
indicate formation of autolysosomes. Right: per-
centage of LC3 reporter present in autolyso-
somes. n = 80 cells per group. *p < 0.05. Scale
bars, 10 mm.
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phatidylinositol 3-phosphate (PtdIns3P) (Eisenberg-Lerner and
Kimchi, 2012), and Vps34-derived PtdIns3P has an established
role in the promotion of autophagosome formation and matura-
tion (Jaber et al., 2012). Because PKD activation was diminished
in fld/fld muscle (Figure 5C), we sought to determine whether
Vps34 activity was affected by assessing the formation of
PtdIns3P. We used a GFP containing the PtdIns3P-binding PX-
domain (phox) from p40 (GFP-p40phox) (Kanai et al., 2001).
When coexpressed with a reporter containing the autophago-
some/autolysosome marker LC3 fused to red fluorescent
protein (mRFP-LC3), it was possible to visualize PtdIns3P
present on autophagosome/autolysosome structures as yellow
puncta. Serum starvation to induce autophagy led to the
appearance of a greater number of yellow puncta in WT MEFs
(Figure 5F, upper panels) than in fld MEFs (Figure 5F, lower274 Cell Metabolism 20, 267–279, August 5, 2014 ª2014 Elsevier Inc.panels). Quantitation revealed approxi-
mately 50% reduction in PtdIns3P in fld/
fld compared to wild-type cells, consis-
tent with reduced Vps34 activity.
Aprediction from thefindingsdescribed
above is that activatedPKDshould rescueautophagy flux observed in lipin-1-deficient cells. To test this, we
coexpressed constitutively active PKD (S738E/742E) (Storz et al.,
2003) with the RFP-GFP-LC3 reporter (Kimura et al., 2007) in fld
MEFs. The expression of active PKD rescued autolysosome
formation in fld MEFs to nearly the level observed in WT MEFs
(Figure 5G). These results indicate that lipin-1/DAG signaling is a
critical component of the PKD-Vps34 signaling cascade and
that disruption of this cascade is a likely cause of apparently
impaired autophagy flux in lipin-1-deficient muscle.
Statin Diminishes mTOR Protein Abundance and
Promotes Abnormal Lipid Accumulation in Combination
with Lipin-1 Haploinsufficiency
We next investigated the mechanisms underlying statin-induced
myopathy in lipin-1-haploinsufficient mice and statin-exacer-
bated myopathy in lipin-1-deficient mice. Although statins have
Figure 6. Statin ReducesmTOR Abundance
and Promotes Lipid Accumulation in Lipin-
1-Deficient and -Haploinsufficient Muscle
(A) Immunoblot assessment of Akt/FoxO3 and
mTOR pathways in skeletal muscle using the
indicated antibodies.
(B) Statin-induced reduction in mTOR levels of
lipin-1-haploinsufficient (wt/fld) muscle.
(C) Muscle-specific lipin-1 transgene prevents
statin-induced reduction in mTOR abundance in
fld/fld muscle.
(D–F) Mass spectrometry analysis was performed
in hindlimb muscle from mice under basal condi-
tions and after statin treatment (n = 3–6) to quantify
(D) phosphatidic acid (PA), (E) ceramide, and (F)
ether phosphatidylcholine (ePC), phosphatidyl-
choline (PC), and sphingomyelin (SM). *p < 0.05;
**p < 0.01 versus indicated groups; xp < 0.05
versus all other groups.
All bar graphs show the mean ± SD.
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damage (Hanai et al., 2007), 11 weeks of Pravastatin treatment
did not alter the activation of Akt/FoxO3 in wild-type or fld/fld
muscle (Figure 6A). However, statin treatment led to substan-
tially diminished levels of mammalian target of rapamycin
(mTOR) in fld/fld muscle. Both total and phosphorylated mTOR
(p-mTOR) were reduced, and mTOR activity was decreased,
as indicated by diminished phosphorylation of the mTOR target,
p70-S6 kinase (on Thr389) (Figure 6A). The levels of regulatory-
associated protein of mTOR (Raptor) were not affected by
lipin-1 deficiency or statin treatment (Figure 6A). Statin treatment
also reduced mTOR abundance in lipin-1-haploinsufficient mus-
cle (Figure 6B), and the muscle lipin-1 transgene largely restored
the levels of mTOR protein in the muscle of fld/fld mice under
statin treatment (Figure 6C).
Finally, we examined whether statin treatment influenced
muscle lipid content in a manner that compounds the effects
of lipin-1 haploinsufficiency. Statin treatment increased PA
levels in wild-type muscle and lipin-1-haploinsufficient muscle
to levels that were similar to those accumulating in response
to PAP enzyme deficiency in fld/fld muscle (Figure 6D). Acute
statin treatment in C2C12 myotubes increased PA levels by
about 25% (Figure S6). Statin also promoted accumulation
of ceramide, ether phosphatidylcholine, phosphatidylcholine,
and sphingomyelin in lipin-1-hapoinsufficient and lipin-1-defi-
cient muscle (Figures 6E and 6F). Thus, statin treatment exac-
erbates lipid imbalances in lipin-1-deficient muscle and induces
similar lipid abnormalities in lipin-1-haploinsufficient muscle.
Together, reduced lipin-1 levels and statin treatment intersect
to induce autophagy (due to reduced mTOR), but also reduce
the capacity for autophagy flux (due to increased PA andCell Metabolism 20, 267–27reduced PKD activation), leading to
impaired autophagy clearance (Figure 7).
DISCUSSION
The pathogenic mechanism for LPIN1-
related myopathy is unknown. Here, wedescribe an essential role for lipin-1 in maintenance of muscle
integrity through autophagy. Lipin-1 PAP activity is required for
the generation of DAG and activation of the PKD-Vps34 signaling
cascade in autophagy clearance (Figure 7, left panel). In the case
of lipin-1 deficiency, a blockade in PAP activity leads to reduced
DAG levels and impaired activation of PKD-Vps34, preventing
normal maturation of autolysosomes (Figure 7, right panel, red
arrows). These defects likely contribute to rhabdomyolysis
observed in lipin-1 deficiency. We uncovered intersecting ac-
tions of lipin-1 and statin drugs on components of this pathway.
Like lipin-1 deficiency, statin treatment caused PA accumulation
and reduced PKD activation, even in wild-type mice (Figure 7,
right panel, blue arrows). Additionally, statin treatment of lipin-
1-deficient and -haploinsufficient mice led to reduced mTOR
activity, which is a trigger for autophagy induction. The combina-
tion of enhanced autophagy initiation and impaired capacity for
flux through the pathway induced statin-related myopathy in
mice with reduced lipin-1 activity.
We determined that lipin-1 PAP activity is critical both for acti-
vation of the PKD-Vps34 pathway and for TAG synthesis and
storage in muscle. Previous studies showed that DAG formation
by PAP activity is important for activation of PKD in Golgi vesicle
trafficking, but it was unclear whether one of the lipin PAP
enzymes or the lipid phosphate phosphatases (previously known
as PAP2 enzymes) are responsible (Asp et al., 2009; Baron
and Malhotra, 2002; Ferna´ndez-Ulibarri et al., 2007). Here, we
demonstrate that lipin-1 PAP activity is required for PKD activa-
tion and fusion of autophagosomes to lysosomes. The addition
of exogenous dipalmitoylglycerol or expression of constitutively
active PKD both largely rescued autophagy flux in lipin-1-
deficient cells. This defines a role for lipin-1 enzyme activity in9, August 5, 2014 ª2014 Elsevier Inc. 275
Figure 7. Proposed Role of Lipin-1 in Regulation of Lipid Levels,
Autophagy Clearance, and Protection against Statin Myotoxicity
Left: in wild-type muscle, lipin-1 converts PA to DAG, providing substrate for
TAG synthesis and activating PKD, with subsequent activation of Vps34 during
autolysosome assembly. These steps allow normal autophagy flux. Right: in
lipin-1 deficiency (red arrows and lines), the lipin-1 enzyme substrate, PA,
accumulates, and DAG levels are reduced. This causes impaired TAG syn-
thesis, reduced PKD/Vps34 activation (active forms signified by asterisk), and
reduced autophagic flux. Statin treatment has effects similar to those of lipin-1
deficiency at some points (blue arrows and lines). Statins cause increased PA
accumulation and reduced PKD activation in both wild-type and lipin-1-hap-
loinsufficient backgrounds. In addition, statin treatment in combination with
lipin-1 haploinsufficiency or lipin-1 deficiency causes reduced mTOR activa-
tion and autophagy initiation. The net result of statin treatment and reduced
lipin-1 activity is to increase autophagy initiation but prevent optimal flux
through the pathway, leading to impaired autophagy clearance.
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could be a potential therapeutic approach for treatment of
lipin-1-related rhabdomyolysis.
Our results also demonstrate that lipin-1 controls TAG storage
in muscle. We previously showed that lipin-1 transgene expres-
sion in muscle of wild-type mice leads to obesity and insulin
resistance, which may be influenced in part by enhanced TAG
accumulation in muscle (Phan and Reue, 2005). The current
study highlights the detrimental effects of lipin-1 deficiency on
lipid homeostasis in muscle. Failure to synthesize and store
TAG led to an accumulation of unesterified fatty acids. A recent
study demonstrated that myocytes isolated from lipin-1-defi-
cient patients also accumulate fatty acids and suggested that
increased fatty acid synthesis may contribute (Michot et al.,
2013). We did not observe evidence for increased fatty acid syn-
thesis, but we did observe increased neutral lipid content in the
form of cholesteryl ester; we suspect that cholesteryl ester also
accounts for the neutral lipid droplets appearing in human lipin-
1-deficient muscle. Cholesteryl esters may accumulate as an
alternative pathway to neutralize excess fatty acids in the
absence of TAG synthesis. It is also possible that the accumula-
tion of fatty acids, phospholipids, and ceramides in lipin-1-defi-
cient muscle contributes to the impaired autophagy and/or
mitochondrial function observed (Las et al., 2011).
Autophagy has an important housekeeping role in the routine
clearance of protein aggregates and damaged organelles, and
the accumulation of abnormal mitochondria in lipin-1-deficient
muscle may result from impaired autophagic flux. Autophagy
can also serve to nonselectively degrade cytosolic contents to276 Cell Metabolism 20, 267–279, August 5, 2014 ª2014 Elsevier Incsupply cells with essential macromolecules and energy and to
ensure cellular survival during starvation (Levine and Kroemer,
2008). A mysterious aspect of human lipin-1 deficiency is
that patients exhibit normal muscle function between rhabdo-
myolytic episodes, suggesting that mitochondrial function is
adequate to meet energy demands during everyday activities.
The rhabdomyolitic episodes are typically associated with fast-
ing or intense exercise. Since fasting and exercise also trigger
autophagy (He et al., 2012), it is possible that the demand for
autophagy during these stresses provides the basis for induction
of muscle damage in lipin-1-deficient individuals under specific
circumstances.
The observation that heterozygous LPIN1 mutation can be
associated with statin-induced myopathy inspired us to investi-
gate the potential convergence of lipin-1 function and statin
toxicity. We determined that a 50% reduction of Lpin1 expres-
sion in mouse, similar to what may occur in the heterozygous
carriers of inactivating LPIN1mutations, promotes muscle dam-
age in a statin-dependent manner. In our model, statins impaired
intramuscular lipid homeostasis, as indicated by the accumu-
lation of free fatty acid (FFA), PA, ether phospholipids, and
ceramides. Interestingly, statin treatment in vivo produced two
alterations that were also observed as a consequence of lipin-
1 deficiency—increased PA levels and reduced PKD activa-
tion—and these effects occurred even in wild-type mice. PA
levels were also increased by treatment with three different sta-
tins in C2C12 myocytes. These observations raise the question
of whether statins act to inhibit lipin-1. We determined that statin
treatment does not reduce Lpin1mRNA levels in mouse muscle.
However, it remains possible that statins increase PA levels
through altering lipin-1 protein localization or stabilization, or
through lipin-1-independent processes, such as activation of
diacylglycerol kinase or phospholipase D. Along these lines,
lovastatin enhances the catalytic activity of phospholipase D2,
promoting PA production (Cho et al., 2011).
Statin treatment in combination with lipin-1 haploinsufficiency
or lipin-1 deficiency produced more severe aberrations in
cellular lipid homeostasis than with either perturbation alone
(i.e., increased levels of several phospholipids and sphingomye-
lin). Together, impaired lipin-1 levels and statin treatment also led
to reduced mTOR and phospho-mTOR abundance. It has been
demonstrated that persistent inactivation of mTORC1 blocks
autophagy clearance and induces myopathy (Ching et al.,
2013; Yu et al., 2010). Thus, the combined effect of statin treat-
ment and reduced lipin-1 content in heterozygous mice may
account for the phenotype similar (although less severe) to that
observed in lipin-1-deficient mice. It should be noted that the
majority of muscle symptoms reported by individuals taking
statin drugs are not accompanied by biochemical or patholog-
ical evidence of muscle disease, and the adverse muscle effects
described here are most relevant to the rare cases of statin-
induced rhabdomyolysis. Our data suggest that heterozygous
carriers of LPIN1 mutations, which have been detected in the
general population (http://www.1000genomes.org/data), may
be at risk for statin-induced rhabdomyolysis.
In summary, we demonstrate that lipin-1 PAP activity func-
tions in autophagy to activate the PKD-Vps34 cascade to pro-
mote autolysosome maturation. The loss of lipin-1 activity leads
to an accumulation of aberrant mitochondria and lipids in.
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Lipin-1 Regulates Autophagy Clearanceskeletal muscle. Statin treatment also impairs PKD activation,
which is compounded by lipin-1 deficiency or haploinsufficiency.
The demonstration that lipin-1 is required for autophagy clear-




BALB/cByJ Lpin1wt/fld mice were obtained from the Jackson Laboratory and
bred to generate mice of desired genotypes. We generated mice with lipin-1
expression exclusively in muscle by crossing a MCK (muscle creatine
kinase)-lipin-1 transgene onto the Lpin1fld/fld background as we did previously
(Phan and Reue, 2005). For statin treatment, Pravastatin (150 mg/ml) was
administered to female mice (aged 2–3 months) in the drinking water, with
an average consumption of 2.5 ml/day/mouse for 11 weeks. In pilot experi-
ments, circulating creatine kinase levels were elevated in fld/fld mice most
significantly in a refed state, and mice were therefore fasted 16 hr and refed
for 5 hr (0800–1300) before blood and tissue collection. The Institutional Animal
Care and Use Committee of the University of California, Los Angeles approved
all animal experimental protocols.
Plasma Creatine Kinase Activity Analysis
Plasma creatine kinase activity was determined using a colorimetric detection
kit (Pointe Scientific) according to the manufacturer’s instructions.
Histological Analysis of Skeletal Muscle
The whole muscle mass was dissected from the lower hindlimbs of mice,
mounted onto a filter paper, and then snap-frozen in liquid nitrogen. The frozen
cross-sections frommidbelly of eachmuscle were stained with a battery of his-
tochemical stains, including hematoxylin and eosin (H&E), oil redO, andNADH-
tetrazoliumreductaseaspreviouslydescribed (Verity, 1991).Necroticmyofibers
were scored inH&Estained sections aspale, swollen fibers that had evidence of
breaks in themusclefibermembrane (Haller andDrachman,1980). Toquantitate
occurrenceofnecrotic fibersor central nucleatedfibers, nonoverlapping images
of the transverse sections were tiled together to provide an entiremuscle cross-
section, and fibers were counted on the entiremuscle section using ImageJ (Liu
et al., 2011). To plot the frequency distribution of fiber area, approximately 500
and 300 fibers randomly selected from cross-sections of tibialis anterior and
soleusmuscle, respectively, were analyzed with ImageJ (threemice per group).
Lipid Analyses
Lipid analyses were performed as previously described (Zhang et al., 2012).
Briefly, lipids were extracted from the lower hindlimb muscle of mice by a
modification of the Bligh and Dyer method. Phospholipid, sphingolipid, and
diacylglycerol species were quantitated by electrospray ionization-tandem
mass spectrometry. Triacylglycerol, free cholesterol, cholesteryl ester, and
free fatty acid levels were determined using reagents fromWako. PA in primary
MEFs or C2C12 myocytes was determined with a Total Phosphatidic Acid kit
(Cayman) (Zhang et al., 2012), and DAG was assessed with a mouse DAG
ELISA kit (MyBioSource) (Cai and Sewer, 2013).
Muscle Oxygen Consumption Rate Measurements
Soleus muscle was isolated from mice, immediately finely minced in PBS,
and placed in the bottom of a Seahorse Islet Capture Microplate, and oxygen
consumption was assessed with the Seahorse XF Extracellular Flux Analyzer
(Seahorse Bioscience) as described previously (Vergnes et al., 2011).
Autophagy Analyses
Autophagic flux was assessed with the RFP-GFP-LC3 reporter plasmid
(ptfLC3) as described (Kimura et al., 2007). Primary MEF cells split in a 12-
well plate were infected with lipin-1 adenoviruses for 16 hr and then trans-
fected with ptfLC3 using BioT transfection reagent (Bioland Scientific). Images
were acquired with a confocal laser scanningmicroscope (Leica SP2 1P-FCS).
Puncta structures with GFP-RFP and/or RFP signals were quantified in more
than 80 cells per group, and the degree of autophagosome maturation was
expressed as the percent of puncta with red color.CelEndogenous Lipin-1, LC3, and LAMP-1 Immunohistochemistry
For colocalization of lipin-1 and LAMP-1, 4-day postdifferentiation C2C12
myotubes were treated with 2 mM rapamycin (Sigma-Aldrich) for 8 hr, 10 mM
lovastatin (Sigma-Aldrich) for 16 hr, or DMSO as control. Immunostaining
was performed as described previously (Peterson et al., 2011). For colocaliza-
tion of LC3 with LAMP-1, primary MEF cells were infected with lipin-1 adeno-
viruses for 16 hr, then transfected for 24 hr and starved with Hank’s balanced
salt solution (HBSS) for 3 hr. Antibodies were obtained from the following
sources: anti-lipin-1 was a kind gift of Dr. Thurl Harris (Harris et al., 2007),
anti-LC3 antibody was from Novus Biologicals, and rat anti-LAMP-1 antibody
was from BD Pharmingen. Images were acquired by confocal laser scanning
microscopy.
Vps34 Activity and PtdIns3P Production Assay
Vps34 activity was detected by visualization of PtdIns3P production on auto-
phagosomes or autolysosomes using the p40phox-EGFP reporter (Kanai et al.,
2001). Primary MEFs were cotransfected with mRFP-LC3 and p40phox-EGFP
plasmids and subcultured onto collagen-coated coverslips. After overnight
incubation, coverslips were washed, and culture medium was replaced with
HBSS for 6 hr. Puncta appearing yellow represent autophagosomes or auto-
lysosomes containing PtdIns3P, whereas puncta appearing red represent
autophagosomes or autolysosomes without PtdIns3P. The percentage of
phagosomes containing PtdIns3P was determined as the proportion of yellow
puncta to total puncta from 80 cells of each group.
Statistical Analyses
The results are shown as mean ± SD. We performed two-way ANOVA or one-
way ANOVA, followed by Bonferroni’s correction for multiple comparisons
(Stata 11). A p value < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2014.05.003.
ACKNOWLEDGMENTS
We gratefully acknowledge Dr. Tamotsu Yoshimori for the gift of GFP-LC3,
mRFP-LC3, and mRFP-GFP-LC3 plasmids; Dr. Michael B. Yaffe for the gift
of p40phox-EGFP reporter plasmids; and Dr. Thurl Harris for anti-lipin-1 anti-
body. We thank Dr. Laurent Vergnes for advice on mitochondrial function
studies, Qin Han for mouse embryonic fibroblast preparation, and Ping Xu
for mouse genotyping and technical assistance. This work was supported
by the National Institutes of Health P01 HL028481 and P01 HL090553 (to
K.R.). The Seahorse XF24 instrument was supported by a shared instrument
grant from the NIH NCRR (S10RR026744). Lipidomic analyses by mass spec-
trometry were performed at the Kansas Lipidomics Research Center Analytical
Laboratory, which was supported by National Science Foundation grants EPS
0236913, MCB 0455318 and 0920663, and DBI 0521587; NIH P20RR16475;
Kansas State University; the Kansas Technology Enterprise Corporation;
and K-IDeA Networks of Biomedical Research Excellence.
Received: December 3, 2013
Revised: March 3, 2014
Accepted: April 21, 2014
Published: June 12, 2014
REFERENCES
Asp, L., Kartberg, F., Fernandez-Rodriguez, J., Smedh, M., Elsner, M.,
Laporte, F., Ba´rcena, M., Jansen, K.A., Valentijn, J.A., Koster, A.J., et al.
(2009). Early stages of Golgi vesicle and tubule formation require diacylgly-
cerol. Mol. Biol. Cell 20, 780–790.
Baron, C.L., and Malhotra, V. (2002). Role of diacylglycerol in PKD recruitment
to the TGN and protein transport to the plasma membrane. Science 295,
325–328.l Metabolism 20, 267–279, August 5, 2014 ª2014 Elsevier Inc. 277
Cell Metabolism
Lipin-1 Regulates Autophagy ClearanceBergounioux, J., Brassier, A., Rambaud, C., Bustarret, O., Michot, C., Hubert,
L., Arnoux, J.B., Laquerriere, A., Bekri, S., Galene-Gromez, S., et al. (2012).
Fatal rhabdomyolysis in 2 children with LPIN1 mutations. J. Pediatr. 160,
1052–1054.
Cai, K., and Sewer, M.B. (2013). cAMP-stimulated transcription of DGKq
requires steroidogenic factor 1 and sterol regulatory element binding protein
1. J. Lipid Res. 54, 2121–2132.
Charge´, S.B.P., and Rudnicki, M.A. (2004). Cellular andmolecular regulation of
muscle regeneration. Physiol. Rev. 84, 209–238.
Ching, J.K., Elizabeth, S.V., Ju, J.S., Lusk, C., Pittman, S.K., and Weihl, C.C.
(2013). mTOR dysfunction contributes to vacuolar pathology and weakness
in valosin-containing protein associated inclusion body myopathy. Hum.
Mol. Genet. 22, 1167–1179.
Cho, K.J., Hill, M.M., Chigurupati, S., Du, G., Parton, R.G., and Hancock, J.F.
(2011). Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase
inhibitor lovastatin activate ras signaling via phospholipase D2. Mol. Cell. Biol.
31, 1110–1120.
Csaki, L.S., Dwyer, J.R., Fong, L.G., Tontonoz, P., Young, S.G., and Reue, K.
(2013). Lipins, lipinopathies, and the modulation of cellular lipid storage and
signaling. Prog. Lipid Res. 52, 305–316.
Donkor, J., Sariahmetoglu, M., Dewald, J., Brindley, D.N., and Reue, K. (2007).
Three mammalian lipins act as phosphatidate phosphatases with distinct
tissue expression patterns. J. Biol. Chem. 282, 3450–3457.
Eaton, J.M., Mullins, G.R., Brindley, D.N., and Harris, T.E. (2013).
Phosphorylation of lipin 1 and charge on the phosphatidic acid head group
control its phosphatidic acid phosphatase activity andmembrane association.
J. Biol. Chem. 288, 9933–9945.
Eisenberg-Lerner, A., and Kimchi, A. (2012). PKD is a kinase of Vps34 that
mediates ROS-induced autophagy downstream of DAPk. Cell Death Differ.
19, 788–797.
Ellwanger, K., Kienzle, C., Lutz, S., Jin, Z.G., Wiekowski, M.T., Pfizenmaier, K.,
and Hausser, A. (2011). Protein kinase D controls voluntary-running-induced
skeletal muscle remodelling. Biochem. J. 440, 327–4.
Ferna´ndez-Ulibarri, I., Vilella, M., La´zaro-Die´guez, F., Sarri, E., Martı´nez, S.E.,
Jime´nez, N., Claro, E., Me´rida, I., Burger, K.N., and Egea, G. (2007).
Diacylglycerol is required for the formation of COPI vesicles in the Golgi-to-
ER transport pathway. Mol. Biol. Cell 18, 3250–3263.
Finck, B.N., Gropler, M.C., Chen, Z., Leone, T.C., Croce, M.A., Harris, T.E.,
Lawrence, J.C., Jr., and Kelly, D.P. (2006). Lipin 1 is an inducible amplifier
of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 4,
199–210.
Germain, M., Nguyen, A.P., Le Grand, J.N., Arbour, N., Vanderluit, J.L., Park,
D.S., Opferman, J.T., and Slack, R.S. (2011). MCL-1 is a stress sensor that
regulates autophagy in a developmentally regulated manner. EMBO J. 30,
395–407.
Haller, R.G., and Drachman, D.B. (1980). Alcoholic rhabdomyolysis: an exper-
imental model in the rat. Science 208, 412–415.
Han, G.S., Wu,W.I., and Carman, G.M. (2006). The Saccharomyces cerevisiae
Lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme.
J. Biol. Chem. 281, 9210–9218.
Hanai, J., Cao, P., Tanksale, P., Imamura, S., Koshimizu, E., Zhao, J., Kishi, S.,
Yamashita, M., Phillips, P.S., Sukhatme, V.P., and Lecker, S.H. (2007). The
muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced
muscle toxicity. J. Clin. Invest. 117, 3940–3951.
Harris, T.E., Huffman, T.A., Chi, A., Shabanowitz, J., Hunt, D.F., Kumar, A., and
Lawrence, J.C., Jr. (2007). Insulin controls subcellular localization andmultisite
phosphorylation of the phosphatidic acid phosphatase, lipin 1. J. Biol. Chem.
282, 277–286.
He, C., Bassik,M.C., Moresi, V., Sun, K.,Wei, Y., Zou, Z., An, Z., Loh, J., Fisher,
J., Sun, Q., et al. (2012). Exercise-induced BCL2-regulated autophagy is
required for muscle glucose homeostasis. Nature 481, 511–515.
Huffman, T.A., Mothe-Satney, I., and Lawrence, J.C., Jr. (2002). Insulin-stimu-
lated phosphorylation of lipinmediated by themammalian target of rapamycin.
Proc. Natl. Acad. Sci. USA 99, 1047–1052.278 Cell Metabolism 20, 267–279, August 5, 2014 ª2014 Elsevier IncHuynh, K.K., Eskelinen, E.-L., Scott, C.C., Malevanets, A., Saftig, P., and
Grinstein, S. (2007). LAMP proteins are required for fusion of lysosomes with
phagosomes. EMBO J. 26, 313–324.
Jaber, N., Dou, Z., Chen, J.S., Catanzaro, J., Jiang, Y.P., Ballou, L.M., Selinger,
E., Ouyang, X., Lin, R.Z., Zhang, J., and Zong,W.X. (2012). Class III PI3K Vps34
plays an essential role in autophagy and in heart and liver function. Proc. Natl.
Acad. Sci. USA 109, 2003–2008.
Jensen, T.E., Maarbjerg, S.J., Rose, A.J., Leitges, M., and Richter, E.A. (2009).
Knockout of the predominant conventional PKC isoform, PKCalpha, in mouse
skeletal muscle does not affect contraction-stimulated glucose uptake. Am. J.
Physiol. Endocrinol. Metab. 297, E340–E348.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T.,
Kominami, E., Ohsumi, Y., and Yoshimori, T. (2000). LC3, a mammalian homo-
logue of yeast Apg8p, is localized in autophagosome membranes after pro-
cessing. EMBO J. 19, 5720–5728.
Kanai, F., Liu, H., Field, S.J., Akbary, H., Matsuo, T., Brown, G.E., Cantley,
L.C., and Yaffe, M.B. (2001). The PX domains of p47phox and p40phox bind
to lipid products of PI(3)K. Nat. Cell Biol. 3, 675–678.
Kim, H.B., Kumar, A., Wang, L., Liu, G.H., Keller, S.R., Lawrence, J.C., Jr.,
Finck, B.N., and Harris, T.E. (2010). Lipin 1 represses NFATc4 transcriptional
activity in adipocytes to inhibit secretion of inflammatory factors. Mol. Cell.
Biol. 30, 3126–3139.
Kimura, S., Noda, T., and Yoshimori, T. (2007). Dissection of the autophago-
some maturation process by a novel reporter protein, tandem fluorescent-
tagged LC3. Autophagy 3, 452–460.
Las, G., Serada, S.B., Wikstrom, J.D., Twig, G., and Shirihai, O.S. (2011). Fatty
acids suppress autophagic turnover in b-cells. J. Biol. Chem. 286, 42534–
42544.
Levine, B., and Kroemer, G. (2008). Autophagy in the pathogenesis of disease.
Cell 132, 27–42.
Liang, C., Lee, J.-S., Inn, K.-S., Gack, M.U., Li, Q., Roberts, E.A., Vergne, I.,
Deretic, V., Feng, P., Akazawa, C., and Jung, J.U. (2008). Beclin1-binding
UVRAG targets the class C Vps complex to coordinate autophagosomematu-
ration and endocytic trafficking. Nat. Cell Biol. 10, 776–787.
Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I.,
Lathrop, M., and Collins, R.; SEARCH Collaborative Group (2008). SLCO1B1
variants and statin-induced myopathy—a genomewide study. N. Engl. J.
Med. 359, 789–799.
Liu, N., Bezprozvannaya, S., Shelton, J.M., Frisard, M.I., Hulver, M.W.,
McMillan, R.P., Wu, Y., Voelker, K.A., Grange, R.W., Richardson, J.A., et al.
(2011). Mice lackingmicroRNA 133a develop dynamin 2–dependent centronu-
clear myopathy. J. Clin. Invest. 121, 3258–3268.
Mangravite, L.M., Engelhardt, B.E., Medina, M.W., Smith, J.D., Brown, C.D.,
Chasman, D.I., Mecham, B.H., Howie, B., Shim, H., Naidoo, D., et al. (2013).
A statin-dependent QTL for GATM expression is associated with statin-
induced myopathy. Nature 502, 377–380.
Michot, C., Hubert, L., Brivet, M., De Meirleir, L., Valayannopoulos, V., Mu¨ller-
Felber, W., Venkateswaran, R., Ogier, H., Desguerre, I., Altuzarra, C., et al.
(2010). LPIN1 genemutations: amajor cause of severe rhabdomyolysis in early
childhood. Hum. Mutat. 31, E1564–E1573.
Michot, C., Hubert, L., Romero, N.B., Gouda, A., Mamoune, A., Mathew, S.,
Kirk, E., Viollet, L., Rahman, S., Bekri, S., et al. (2012). Study of LPIN1,
LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia.
J. Inherit. Metab. Dis. 35, 1119–1128.
Michot, C., Mamoune, A., Vamecq, J., Viou, M.T., Hsieh, L.S., Testet, E., Laine´,
J., Hubert, L., Dessein, A.F., Fontaine, M., et al. (2013). Combination of lipid
metabolism alterations and their sensitivity to inflammatory cytokines in
human lipin-1-deficient myoblasts. Biochim. Biophys. Acta 1832, 2103–2114.
Mizushima, N., Yoshimori, T., and Levine, B. (2010). Methods in mammalian
autophagy research. Cell 140, 313–326.
Mohassel, P., and Mammen, A.L. (2013). The spectrum of statin myopathy.
Curr. Opin. Rheumatol. 25, 747–752.
Needham, M., and Mastaglia, F.L. (2014). Statin myotoxicity: a review of
genetic susceptibility factors. Neuromuscul. Disord. 24, 4–15..
Cell Metabolism
Lipin-1 Regulates Autophagy ClearancePascual, F., and Carman, G.M. (2013). Phosphatidate phosphatase, a key
regulator of lipid homeostasis. Biochim. Biophys. Acta 1831, 514–522.
Pascual, F., Hsieh, L.S., Soto-Cardalda, A.I., and Carman, G.M. (2014). Yeast
Pah1p phosphatidate phosphatase is regulated by proteasome-mediated
degradation. J. Biol. Chem. 289, 9811–9822.
Pe´terfy, M., Phan, J., Xu, P., and Reue, K. (2001). Lipodystrophy in the fld
mouse results from mutation of a new gene encoding a nuclear protein, lipin.
Nat. Genet. 27, 121–124.
Peterson, T.R., Sengupta, S.S., Harris, T.E., Carmack, A.E., Kang, S.A.,
Balderas, E., Guertin, D.A., Madden, K.L., Carpenter, A.E., Finck, B.N., and
Sabatini, D.M. (2011). mTOR complex 1 regulates lipin 1 localization to control
the SREBP pathway. Cell 146, 408–420.
Phan, J., and Reue, K. (2005). Lipin, a lipodystrophy and obesity gene. Cell
Metab. 1, 73–83.
Phillips, P.S., Haas, R.H., Bannykh, S., Hathaway, S., Gray, N.L., Kimura, B.J.,
Vladutiu, G.D., and England, J.D.; Scripps Mercy Clinical Research Center
(2002). Statin-associated myopathy with normal creatine kinase levels. Ann.
Intern. Med. 137, 581–585.
Shahnazari, S., Yen, W.L., Birmingham, C.L., Shiu, J., Namolovan, A., Zheng,
Y.T., Nakayama, K., Klionsky, D.J., and Brumell, J.H. (2010). A diacylglycerol-
dependent signaling pathway contributes to regulation of antibacterial auto-
phagy. Cell Host Microbe 8, 137–146.
Shibasaki, M., Kurokawa, K., Katsura, M., and Ohkuma, S. (2009). Direct
evidence for the up-regulation of Vps34 regulated by PKCgamma during
short-term treatment with morphine. Synapse 63, 365–368.
Storz, P., Do¨ppler, H., Johannes, F.J., and Toker, A. (2003). Tyrosine phos-
phorylation of protein kinase D in the pleckstrin homology domain leads to
activation. J. Biol. Chem. 278, 17969–17976.CelSugden, M.C., Caton, P.W., and Holness, M.J. (2010). PPAR control: it’s
SIRTainly as easy as PGC. J. Endocrinol. 204, 93–104.
Tan, S.H., Shui, G., Zhou, J., Li, J.J., Bay, B.H., Wenk, M.R., and Shen, H.M.
(2012). Induction of autophagy by palmitic acid via protein kinase C-mediated
signaling pathway independent of mTOR (mammalian target of rapamycin).
J. Biol. Chem. 287, 14364–14376.
Thompson, P.D., Clarkson, P., and Karas, R.H. (2003). Statin-associated
myopathy. JAMA 289, 1681–1690.
Ugrankar, R., Liu, Y., Provaznik, J., Schmitt, S., and Lehmann, M. (2011). Lipin
is a central regulator of adipose tissue development and function in Drosophila
melanogaster. Mol. Cell. Biol. 31, 1646–1656.
Vergnes, L., Chin, R., Young, S.G., and Reue, K. (2011). Heart-type fatty
acid-binding protein is essential for efficient brown adipose tissue fatty acid
oxidation and cold tolerance. J. Biol. Chem. 286, 380–390.
Verity, M.A. (1991). Infantile Pompe’s disease, lipid storage, and partial
carnitine deficiency. Muscle Nerve 14, 435–440.
Wang, K., and Klionsky, D.J. (2011). Mitochondria removal by autophagy.
Autophagy 7, 297–300.
Yu, L., McPhee, C.K., Zheng, L., Mardones, G.A., Rong, Y., Peng, J., Mi, N.,
Zhao, Y., Liu, Z., Wan, F., et al. (2010). Termination of autophagy and reforma-
tion of lysosomes regulated by mTOR. Nature 465, 942–946.
Zeharia, A., Shaag, A., Houtkooper, R.H., Hindi, T., de Lonlay, P., Erez, G.,
Hubert, L., Saada, A., de Keyzer, Y., Eshel, G., et al. (2008). Mutations
in LPIN1 cause recurrent acute myoglobinuria in childhood. Am. J. Hum.
Genet. 83, 489–494.
Zhang, P., Takeuchi, K., Csaki, L.S., and Reue, K. (2012). Lipin-1 phosphatidic
phosphatase activity modulates phosphatidate levels to promote peroxisome
proliferator-activated receptor g (PPARg) gene expression during adipogene-
sis. J. Biol. Chem. 287, 3485–3494.l Metabolism 20, 267–279, August 5, 2014 ª2014 Elsevier Inc. 279
